Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ventyx Biosciences, Inc. (VTYX)
:VTYX
RESEARCH TOOLSreports
Holding VTYX?
Track your performance easily
VTYX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.67 - $11.48
Previous CloseN/A
Volume4.54M
Average Volume (3M)1.95M
Market Cap
$133.64M
Enterprise Value-$109.73M
Total Cash (Recent Filing)$309.00K
Total Debt (Recent Filing)$3.85M
Price to Earnings (P/E)―
Beta1.92
Next Earnings
Mar 20, 2025EPS Estimate
-0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.37
Shares Outstanding70,710,670
10 Day Avg. Volume2,063,891
30 Day Avg. Volume1,948,794
Standard Deviation0.48
R-Squared0.00318
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.71
Forecast
1Y Price Target
$11.50Price Target Upside508.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Ventyx Biosciences News
PremiumCompany Announcements
Ventyx Biosciences Unveils 2025 Pipeline and Clinical Updates
PremiumCompany Announcements
Ventyx Biosciences Reports Q3 Financial Results and Pipeline Progress
PremiumStock Analysis & Ideas
These 2 ‘Strong Buy’ Penny Stocks Could Rally Over 500%, Say Analysts
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentPreclinical data shows that VTX3232 combined with semaglutide results in significant body weight reduction and improvement in body composition.
Financial StabilityVentyx has $274.8M in cash and equivalents, expected to fund operations into at least H2 2026, indicating financial stability.
Strategic PartnershipVentyx Biosciences received a $27M strategic investment from Sanofi, which is seen as a validation of the Phase 1 data generated by their NLRP3 inhibitor, VTX3232.
Bears Say
Efficacy ConcernsThere is uncertainty if VTX3232’s oral administration convenience outweighs its lower efficacy compared to semaglutide's subcutaneous method.
Market SkepticismShort interest is at 15.3% of the float, which may suggest some market skepticism about the stock.
Therapy Compliance ChallengesThe practicality of dual obesity-targeting therapy with VTX3232 and semaglutide is approached with caution due to challenges posed by different routes of administration, which could lead to high risk of non-compliance.
---
Ownership Overview
29.71% Insiders
9.15% Mutual Funds
0.02% Other Institutional Investors
52.31% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VTYX FAQ
What was Ventyx Biosciences, Inc.’s price range in the past 12 months?
Ventyx Biosciences, Inc. lowest stock price was $1.67 and its highest was $11.48 in the past 12 months.
What is Ventyx Biosciences, Inc.’s market cap?
Ventyx Biosciences, Inc.’s market cap is $133.64M.
When is Ventyx Biosciences, Inc.’s upcoming earnings report date?
Ventyx Biosciences, Inc.’s upcoming earnings report date is Mar 20, 2025 which is in 61 days.
How were Ventyx Biosciences, Inc.’s earnings last quarter?
Ventyx Biosciences, Inc. released its earnings results on Nov 07, 2024. The company reported -$0.5 earnings per share for the quarter, beating the consensus estimate of -$0.518 by $0.018.
Is Ventyx Biosciences, Inc. overvalued?
According to Wall Street analysts Ventyx Biosciences, Inc.’s price is currently Undervalued.
Does Ventyx Biosciences, Inc. pay dividends?
Ventyx Biosciences, Inc. does not currently pay dividends.
What is Ventyx Biosciences, Inc.’s EPS estimate?
Ventyx Biosciences, Inc.’s EPS estimate is -0.53.
How many shares outstanding does Ventyx Biosciences, Inc. have?
Ventyx Biosciences, Inc. has 70,710,670 shares outstanding.
What happened to Ventyx Biosciences, Inc.’s price movement after its last earnings report?
Ventyx Biosciences, Inc. reported an EPS of -$0.5 in its last earnings report, beating expectations of -$0.518. Following the earnings report the stock price went down -1.786%.
Which hedge fund is a major shareholder of Ventyx Biosciences, Inc.?
Currently, no hedge funds are holding shares in VTYX
---
Ventyx Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.50 (508.47% Upside)
$11.50 (508.47% Upside)
Blogger Sentiment
Bearish
VTYX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 336.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.34%
12-Months-Change
Fundamentals
Return on Equity
-54.24%
Trailing 12-Months
Asset Growth
-6.40%
Trailing 12-Months
Company Description
Ventyx Biosciences, Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
---
VTYX Earnings Call
Q1 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with significant progress in clinical trials for multiple drug candidates, particularly VTX3232 and VTX2735. Financial stability was emphasized, despite a consistent net loss and high cash usage. The company appears to be on a promising path with advancements in its pipeline and preparations for future trials.Read More>---
VTYX Stock 12 Month Forecast
Average Price Target
$11.50
▲(508.47% Upside)
Technical Analysis
Relay Therapeutics
―
Blueprint Medicines
―
Prime Medicine, Inc.
―
Immatics
―
Crinetics Pharmaceuticals
―
vTv Therapeutics
―
Best Analysts Covering VTYX
1 Year
1 Year Success Rate
6/22 ratings generated profit
1 Year Average Return
-15.44%
assigned a buy rating 5 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 27.27% of your transactions generating a profit, with an average return of -15.44% per trade.
---